

CITATION REPORT

List of articles citing

The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval

DOI: 10.1016/j.jacc.2005.05.036

Journal of the American College of Cardiology, 2005, 46, 678-87.

Source: <https://exaly.com/paper-pdf/39443840/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead. <i>Drug Safety</i> , 2005 , 28, 1009-28	5.1	88
27	Making a silk purse out of a sow's ear. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 688-9	15.1	1
26	The year 2005 in electrocardiology. <i>Annals of Noninvasive Electrocardiology</i> , 2006 , 11, 187-93	1.5	8
25	Sex Differences in QT Interval Variability and Implication on Sample Size of Thorough QT Study. <i>Drug Information Journal</i> , 2007 , 41, 619-627		9
24	Does sildenafil cause myocardial infarction or sudden cardiac death?. <i>American Journal of Cardiovascular Drugs</i> , 2008 , 8, 1-7	4	18
23	QT/QTc prolongation in placebo-treated subjects: a PhRMA collaborative data analysis. <i>Journal of Biopharmaceutical Statistics</i> , 2008 , 18, 408-26	1.3	6
22	Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings. <i>Expert Review of Clinical Pharmacology</i> , 2008 , 1, 815-39	3.8	6
21	The cardiovascular safety of tadalafil. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 43-52	4.1	8
20	Sample size calculations in thorough QT studies. <i>Journal of Biopharmaceutical Statistics</i> , 2008 , 18, 468-82	1.3	30
19	Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. <i>British Journal of Pharmacology</i> , 2010 , 159, 34-48	8.6	75
18	A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 159-71	4.4	23
17	Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. <i>Circulation</i> , 2010 , 122, 88-95	16.7	78
16	Thorough QT Studies: Questions and Quandaries. <i>Drug Safety</i> , 2010 , 33, 1-14	5.1	45
15	Effect of number of replicate electrocardiograms recorded at each time point in a thorough QT study on sample size and study cost. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 908-14	2.9	15
14	Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011 , 34, 1116-27	1.6	2
13	Computerized extraction of electrocardiograms from continuous 12-lead holter recordings reduces measurement variability in a thorough QT study. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 1891-900	2.9	9
12	Early investigation of QTc liability: the role of multiple ascending dose (MAD) study. <i>Drug Safety</i> , 2012 , 35, 695-709	5.1	28

11	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 747-55	4	13
10	Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. <i>Drugs and Aging</i> , 2012 , 29, 771-81	4.7	8
9	Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation. <i>Congestive Heart Failure</i> , 2012 , 18, 229-33		13
8	Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 538-49	3.8	9
7	Detecting moxifloxacin-induced QTc prolongation in thorough QT and early clinical phase studies using a highly automated ECG analysis approach. <i>British Journal of Pharmacology</i> , 2016 , 173, 1373-80	8.6	13
6	Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?. <i>Heart</i> , 2018 , 104, 1244-1250	5.1	43
5	Individual-Specific QT Interval Correction for Drugs With Substantial Heart Rate Effect Using Holter ECGs Extracted Over a Wide Range of Heart Rates. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1013-1019	3.9	4
4	Early Investigation of QTc Liability. 2012 , 35, 695		2
3	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
2	Linear Mixed Effects Models. 2011 , 189-232		
1	Combination of Sildenafil and Ba at a Low Concentration Show a Significant Synergistic Inhibition of Inward Rectifier Potassium Current Resulting in Action Potential Prolongation.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 829952	5.6	0